ACADIA Pharmaceuticals(ACAD) - 2025 Q4 - Annual Results

Financial Performance - Acadia Pharmaceuticals anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance[6] Corporate Events - The company presented at the J.P. Morgan Healthcare Conference on January 13, 2026[6] - A corporate slide presentation was posted on the company's investor website[6] Regulatory Filings - The report is filed under the Securities Exchange Act of 1934[8] - The company has not elected to use the extended transition period for new financial accounting standards[5] - No emerging growth company status was indicated in the filing[5] - The report includes a Regulation FD disclosure[7] - The financial statements and exhibits are part of the filing[9] - The report was signed by Jennifer J. Rhodes, Executive Vice President, Chief Legal Officer & Secretary[13] Stock Information - Acadia Pharmaceuticals is listed on The Nasdaq Stock Market under the symbol ACAD[5]